Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) was up 14% during trading on Friday . The stock traded as high as $0.51 and last traded at $0.49. Approximately 1,049,643 shares changed hands during trading, an increase of 58% from the average daily volume of 663,791 shares. The stock had previously closed at $0.43.
Several equities research analysts have recently commented on PLX shares. HC Wainwright set a $4.00 price target on shares of Protalix Biotherapeutics and gave the company a “buy” rating in a research report on Thursday, December 13th. Zacks Investment Research raised shares of Protalix Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, February 21st.
A number of institutional investors have recently added to or reduced their stakes in PLX. Fosun International Ltd purchased a new stake in Protalix Biotherapeutics in the 3rd quarter worth approximately $1,881,000. Renaissance Technologies LLC increased its holdings in Protalix Biotherapeutics by 24.9% in the 3rd quarter. Renaissance Technologies LLC now owns 3,266,401 shares of the company’s stock worth $2,374,000 after acquiring an additional 651,701 shares in the last quarter. Finally, Virtu Financial LLC increased its holdings in Protalix Biotherapeutics by 44.4% in the 4th quarter. Virtu Financial LLC now owns 91,862 shares of the company’s stock worth $29,000 after acquiring an additional 28,236 shares in the last quarter.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Modern Readers and is the sole property of of Modern Readers. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.modernreaders.com/news/2019/03/17/protalix-biotherapeutics-plx-trading-up-14.html.
About Protalix Biotherapeutics (NYSEAMERICAN:PLX)
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.
Read More: What is a Stop Order?
Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.